LAB Q1 2021 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$388M

Q1 2021 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$33M+18.7% YoY

Gross Profit

$19M58.1% margin

Operating Income

-$19M-58.9% margin

Net Income

-$19M-57.4% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

-26.5%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$20M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$305M

Total Liabilities

$182M

Stockholders' Equity

$123M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$28M	+18.7%
Gross Profit	$19M	$16M	+15.7%
Operating Income	-$19M	-$15M	-29.3%
Net Income	-$19M	-$16M	-17.8%

Revenue Segments

Product

$25M43%

Consumables

$17M29%

Instruments

$8M13%

Service

$6M11%

Collaboration Revenue

$1M3%

Product and Service, Other

$300,0001%

Grant

$300,0001%

Geographic Segments

Americas

$19M56%

EMEA

$9M28%

Asia Pacific

$5M16%